What form of HRT is safest now?

Based on current clinical evidence, transdermal estrogen (delivered through the skin) combined with micronized progesterone is considered the preferred modern HRT approach for most women — though whether this or any HRT is appropriate depends on individual health factors that a prescriber must evaluate.

Why this combination is currently preferred

According to current NAMS guidelines, transdermal estrogen bypasses first-pass hepatic metabolism, which is associated with a lower risk of venous thromboembolism and stroke compared with oral estrogen preparations. Per the Endocrine Society, micronized progesterone is a body-identical progestogen that protects the uterine lining and is associated with a more favorable cardiovascular and breast safety profile compared with older synthetic progestins.

Estrogen delivery options in current clinical use

• Transdermal estrogen patch: According to current NAMS guidelines, patches provide stable serum estradiol levels and are associated with a lower thromboembolic risk than oral formulations. They are among the most extensively studied delivery methods.
• Estrogen gel or spray: Per published clinical guidelines, transdermal gels and sprays offer comparable pharmacokinetic benefits to patches and allow flexible dose titration.
• Compounded topical estrogen creams: May be used when standard commercially available doses are not clinically suitable. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs. Both FDA-approved products (such as estradiol and micronized progesterone) and compounded preparations may contain bioidentical hormones. The term does not indicate superiority of one category over another.

Progesterone options in current clinical use

• Micronized progesterone (oral capsule): Per the Endocrine Society, micronized progesterone is body-identical and is associated with a more favorable breast and clotting risk profile compared with synthetic progestins. It may also have a favorable effect on sleep quality.
• Vaginal progesterone: Per published clinical guidelines, vaginal administration delivers progesterone directly to uterine tissue and may be preferred when systemic side effects from oral formulations are a concern.
• Compounded progesterone: May be considered for individuals who require tailored dosing or cannot tolerate standard capsule formulations. The same compounding notice and bioidentical caveat above apply.

Clinical scenarios where this combination is frequently preferred

• History of migraines: According to current NAMS guidelines, transdermal estrogen maintains more stable serum levels and may reduce hormonally triggered migraine frequency compared with cyclical oral preparations.
• Elevated thromboembolic risk or relevant family history: Per the Endocrine Society, transdermal delivery avoids the prothrombotic effects associated with oral estrogen and is preferred in women with identifiable clot risk factors.
• Perimenopause with mood sensitivity: Per published clinical guidelines, micronized progesterone has a more favorable neurological tolerability profile than synthetic progestins, which may benefit individuals sensitive to mood-related side effects.

Summary

According to current NAMS guidelines and the Endocrine Society, transdermal estradiol combined with micronized progesterone represents a well-studied approach that is currently favored in clinical practice for eligible women. However, the suitability of any HRT regimen — including this combination — depends on a complete individual medical history. A prescriber should determine the most appropriate form, dose, and delivery route based on each patient's clinical profile and personal health factors.